BridgeBio Pharma (NASDAQ: BBIO) — Perfil da empresa, notícias e dados financeiros
BridgeBio Pharma is a biopharmaceutical company focused on breakthrough medicines for genetic diseases and cancers.
BridgeBio Pharma
BridgeBio Pharma is a commercial-stage biopharmaceutical company focused on discovering, developing, and delivering transformative medicines for patients with genetic diseases and cancers with clear genetic drivers. Founded in 2015, the company targets diseases at their root cause by developing targeted therapies across various therapeutic areas, including cardiology, oncology, and rare genetic disorders. Its portfolio features approved therapies such as Attruby (acoramidis) for transthyretin amyloid cardiomyopathy and Nulibry (fosdenopterin) for molybdenum cofactor deficiency type A, along with advanced clinical pipeline candidates like infigratinib, encaleret, and BBP-418.
Resumo
Operações
Produtos e/ou serviços de BridgeBio Pharma
- Transthyretin Stabilizers: Attruby (acoramidis) is an orally administered transthyretin stabilizer approved for treating transthyretin amyloid cardiomyopathy and undergoing evaluation for variant transthyretin amyloidosis to slow disease progression by preventing tetramer dissociation.
- Metabolic Therapies: Nulibry (fosdenopterin) is an injectable substrate replacement therapy indicated to reduce mortality risk in patients with molybdenum cofactor deficiency Type A, a rare, fatal metabolic disorder caused by deficiency in cyclic pyranopterin monophosphate.
- Skeletal Dysplasia Programs: Infigratinib is an orally administered, selective FGFR1-3 tyrosine kinase inhibitor undergoing Phase 3 clinical trials for the treatment of pediatric skeletal dysplasias, specifically targeting achondroplasia and hypochondroplasia to promote linear bone growth.
- Endocrine Therapies: Encaleret is an oral small molecule antagonist of the calcium-sensing receptor currently in Phase 3 clinical trials designed to normalize serum calcium and urinary excretion in patients with autosomal dominant hypocalcemia type 1.
- Muscular Dystrophy Candidates: BBP-418 is an investigational oral prodrug of ribitol in Phase 3 development designed to restore glycosylation of alpha-dystroglycan in patients suffering from limb-girdle muscular dystrophy type 2I/R9 caused by mutations in FKRP.
- Gene Therapies: BBP-812 is an investigational AAV9-based gene therapy designed to restore functional ASPA enzyme expression in the central nervous system for infants and children affected by Canavan disease, a severe, progressive neurodegenerative disorder.
equipe executiva do BridgeBio Pharma
- Neil KumarCo-Founder, CEO & Director
- Thomas TrimarchiCFO & President
- Charles J. HomcyCo-Founder, Chairman of Pharmaceuticals & Lead Director
- Frank P. McCormickCo-Founder, Chairman of Oncology & Director
- Maricel M. ApuliChief Accounting Officer
- Uma SinhaChief Scientific Officer
- Richard H. SchellerChairman of Research & Development
- Eli M. WallaceChief Scientific Officer of Oncology
- Eric Michael DavidChief Executive Officer of Gene Therapy
- Matthew OuttenChief Commercial Officer
Últimas notícias sobre a BridgeBio Pharma
Principais indicadores financeiros
Resultados divulgados pela BridgeBio Pharma, em USD.
- Cap. de mercado
- 13,8 bi
- Receita (TTM)
- 713,1 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.6
- Dividend yield
- —
- Margem de lucro
- -97.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 502,1 mi | -569,1 mi | -729,3 mi | |
| 221,9 mi | -593 mi | -535,8 mi | |
| 9,3 mi | -607,4 mi | -643,2 mi | |
| 77,6 mi | -512,2 mi | -481,2 mi |